4Q 2022 Financial Results & Business Update

J.P. Morgan Healthcare Conference Presentation

Binding and Signal Profiling of Full and Partial M4 Agonists

Efficacy of Subtype-Selective, Full vs Partial M4 Muscarinic Receptor Agonists in Modulating Amphetamine-Induced Brain Activity Assessed by Functional MRI (fMRI) in Rats

Efficacy of CV-0000042, a Novel M4 Receptor Full Agonist, and CV-0000071, a Novel M4 Receptor Partial Agonist, in Preclinical In Vivo Models of Psychosis

3Q 2022 Financial Results & Business Update

Cerevel Corporate Presentation - September

2Q 2022 Financial Results & Business Update

IARPD 2022 Poster - Setting the TEMPO: A Phase 3 Program to Investigate Tavapadon, a Selective D1/D5 Partial Agonist, for Parkinson’s Disease

1Q 2022 Financial Results & Business Update